Tokyo Tape
Sign in
← PHC Holdings

Half-year report · HY

6523.TEDINET S100X235
Period2025-04-01 → 2025-09-30
Filed2025-11-12
StandardIFRS
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 47
MetricValuePeriodScopeSource row
Revenue¥173.4bn2025-04-01 → 2025-09-30Cons.Revenue IFRS
Revenue¥361.6bn2024-04-01 → 2025-03-31Cons.Revenue IFRS (5-year summary)
Revenue¥173.9bn2024-04-01 → 2024-09-30Cons.Revenue IFRS
Operating income¥10.4bn2025-04-01 → 2025-09-30Cons.Operating profit loss IFRS
Operating income¥9.2bn2024-04-01 → 2024-09-30Cons.Operating profit loss IFRS
Profit before tax¥941m2025-04-01 → 2025-09-30Cons.Profit loss before tax IFRS
Profit before tax¥18.8bn2024-04-01 → 2025-03-31Cons.Profit loss before tax IFRS (5-year summary)
Profit before tax¥7.4bn2024-04-01 → 2024-09-30Cons.Profit loss before tax IFRS
Net income (owners)−¥559m2025-04-01 → 2025-09-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥10.5bn2024-04-01 → 2025-03-31Cons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)¥4.1bn2024-04-01 → 2024-09-30Cons.Profit loss attributable to owners of parent IFRS
Net income−¥692m2025-04-01 → 2025-09-30Cons.Profit loss IFRS
Net income¥4.0bn2024-04-01 → 2024-09-30Cons.Profit loss IFRS
Total assets¥525.8bnat 2025-09-30Cons.Assets IFRS
Total assets¥532.5bnat 2025-03-31Cons.Assets IFRS
Total assets¥525.4bnat 2024-09-30Cons.Total assets IFRS (5-year summary)
Total liabilities¥379.8bnat 2025-09-30Cons.Liabilities IFRS
Total liabilities¥391.3bnat 2025-03-31Cons.Liabilities IFRS
Net assets / equity¥146.0bnat 2025-09-30Cons.Equity IFRS
Net assets / equity¥141.2bnat 2025-03-31Cons.Equity IFRS
Net assets / equity¥127.4bnat 2024-09-30Cons.Equity IFRS
Net assets / equity¥139.2bnat 2024-03-31vCons.Equity IFRS
Equity (owners)¥146.7bnat 2025-09-30Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥141.6bnat 2025-03-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥127.8bnat 2024-09-30Cons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥33.3bnat 2025-09-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥39.6bnat 2025-03-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥33.0bnat 2024-09-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥47.0bnat 2024-03-31vCons.Cash and cash equivalents IFRS
Operating cash flow¥12.1bn2025-04-01 → 2025-09-30Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥41.9bn2024-04-01 → 2025-03-31Cons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥13.8bn2024-04-01 → 2024-09-30Cons.Net cash provided by used in operating activities IFRS
Investing cash flow−¥4.2bn2025-04-01 → 2025-09-30Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥8.5bn2024-04-01 → 2025-03-31Cons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥5.0bn2024-04-01 → 2024-09-30Cons.Net cash provided by used in investing activities IFRS
Financing cash flow−¥17.6bn2025-04-01 → 2025-09-30Cons.Net cash provided by used in financing activities IFRS
Financing cash flow−¥39.1bn2024-04-01 → 2025-03-31Cons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow−¥20.9bn2024-04-01 → 2024-09-30Cons.Net cash provided by used in financing activities IFRS
EPS (basic)¥-4.422025-04-01 → 2025-09-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥83.132024-04-01 → 2025-03-31Cons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥32.522024-04-01 → 2024-09-30Cons.Basic earnings loss per share IFRS
EPS (diluted)¥-4.422025-04-01 → 2025-09-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥82.582024-04-01 → 2025-03-31Cons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥32.422024-04-01 → 2024-09-30Cons.Diluted earnings loss per share IFRS
Equity ratio27.9%at 2025-09-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio26.6%at 2025-03-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio24.3%at 2024-09-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 30
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2025-04-01 → 2025-09-30¥2.9bn
Reconciling Itemsreconcilingrevenue external2025-04-01 → 2025-09-30¥2.9bn
Reconciling Itemsreconcilingsegment profit2025-04-01 → 2025-09-30−¥3.2bn
Diabetes Managementreportable segmentrevenue2025-04-01 → 2025-09-30¥48.7bn
Diabetes Managementreportable segmentrevenue external2025-04-01 → 2025-09-30¥48.7bn
Diabetes Managementreportable segmentsegment profit2025-04-01 → 2025-09-30¥9.3bn
Diagnostics And Life Sciencesreportable segmentrevenue2025-04-01 → 2025-09-30¥59.1bn
Diagnostics And Life Sciencesreportable segmentrevenue external2025-04-01 → 2025-09-30¥59.1bn
Diagnostics And Life Sciencesreportable segmentsegment profit2025-04-01 → 2025-09-30¥1.3bn
Healthcare Solutionsreportable segmentrevenue2025-04-01 → 2025-09-30¥62.7bn
Healthcare Solutionsreportable segmentrevenue external2025-04-01 → 2025-09-30¥62.7bn
Healthcare Solutionsreportable segmentsegment profit2025-04-01 → 2025-09-30¥3.0bn
—segment totalrevenue2025-04-01 → 2025-09-30¥170.5bn
—segment totalrevenue external2025-04-01 → 2025-09-30¥170.5bn
—segment totalsegment profit2025-04-01 → 2025-09-30¥13.6bn
Reconciling Itemsreconcilingrevenue2024-04-01 → 2024-09-30¥1.6bn
Reconciling Itemsreconcilingrevenue external2024-04-01 → 2024-09-30¥1.6bn
Reconciling Itemsreconcilingsegment profit2024-04-01 → 2024-09-30−¥4.3bn
Diabetes Managementreportable segmentrevenue2024-04-01 → 2024-09-30¥48.3bn
Diabetes Managementreportable segmentrevenue external2024-04-01 → 2024-09-30¥48.3bn
Diabetes Managementreportable segmentsegment profit2024-04-01 → 2024-09-30¥6.4bn
Diagnostics And Life Sciencesreportable segmentrevenue2024-04-01 → 2024-09-30¥62.6bn
Diagnostics And Life Sciencesreportable segmentrevenue external2024-04-01 → 2024-09-30¥62.6bn
Diagnostics And Life Sciencesreportable segmentsegment profit2024-04-01 → 2024-09-30¥3.5bn
Healthcare Solutionsreportable segmentrevenue2024-04-01 → 2024-09-30¥61.5bn
Healthcare Solutionsreportable segmentrevenue external2024-04-01 → 2024-09-30¥61.5bn
Healthcare Solutionsreportable segmentsegment profit2024-04-01 → 2024-09-30¥3.6bn
—segment totalrevenue2024-04-01 → 2024-09-30¥172.3bn
—segment totalrevenue external2024-04-01 → 2024-09-30¥172.3bn
—segment totalsegment profit2024-04-01 → 2024-09-30¥13.5bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 753
ItemContextValueUnit
Repayments of lease obligations fin cf IFRSPrior1InterimDuration-3631000000JPY
Repayments of lease obligations fin cf IFRSInterimDuration-2963000000JPY
Proceeds from issuance of shares fin cf IFRSPrior1InterimDuration37000000JPY
Proceeds from issuance of shares fin cf IFRSInterimDuration0JPY
Dividends paid to owners of parent fin cf IFRSPrior1InterimDuration-2268000000JPY
Dividends paid to owners of parent fin cf IFRSInterimDuration-2649000000JPY
Other fin cf IFRSPrior1InterimDuration-14000000JPY
Other fin cf IFRSInterimDuration-13000000JPY
Net cash provided by used in financing activities IFRSPrior1InterimDuration-20920000000JPY
Net cash provided by used in financing activities IFRSInterimDuration-17562000000JPY
Effect of exchange rate changes on cash and cash equivalents IFRSPrior1InterimDuration-1937000000JPY
Effect of exchange rate changes on cash and cash equivalents IFRSInterimDuration3435000000JPY
Net increase decrease in cash and cash equivalents IFRSPrior1InterimDuration-14074000000JPY
Net increase decrease in cash and cash equivalents IFRSInterimDuration-6283000000JPY
Cash and cash equivalents IFRSPrior2YearInstant47044000000JPY
Cash and cash equivalents IFRSPrior1YearInstant39592000000JPY
Cash and cash equivalents IFRSPrior1InterimInstant32969000000JPY
Cash and cash equivalents IFRSInterimInstant33309000000JPY
Revenue from external customers IFRSPrior1InterimDuration_jpcrp040300-ssr_E36976-000DiabetesManagementReportableSegmentMember48259000000JPY
Revenue from external customers IFRSPrior1InterimDuration_jpcrp040300-ssr_E36976-000HealthcareSolutionsReportableSegmentMember61484000000JPY
Revenue from external customers IFRSPrior1InterimDuration_jpcrp040300-ssr_E36976-000DiagnosticsAndLifeSciencesReportableSegmentMember62561000000JPY
Revenue from external customers IFRSPrior1InterimDuration_ReportableSegmentsMember172305000000JPY
Revenue from external customers IFRSPrior1InterimDuration_ReconcilingItemsMember1557000000JPY
Revenue from external customers IFRSPrior1InterimDuration173863000000JPY
Intersegment revenue IFRSPrior1InterimDuration_jpcrp040300-ssr_E36976-000DiabetesManagementReportableSegmentMember－JPY
Intersegment revenue IFRSPrior1InterimDuration_jpcrp040300-ssr_E36976-000HealthcareSolutionsReportableSegmentMember－JPY
Intersegment revenue IFRSPrior1InterimDuration_jpcrp040300-ssr_E36976-000DiagnosticsAndLifeSciencesReportableSegmentMember－JPY
Intersegment revenue IFRSPrior1InterimDuration_ReportableSegmentsMember－JPY
Intersegment revenue IFRSPrior1InterimDuration_ReconcilingItemsMember－JPY
Intersegment revenue IFRSPrior1InterimDuration－JPY
Revenue IFRSPrior1InterimDuration_jpcrp040300-ssr_E36976-000DiabetesManagementReportableSegmentMember48259000000JPY
Revenue IFRSPrior1InterimDuration_jpcrp040300-ssr_E36976-000HealthcareSolutionsReportableSegmentMember61484000000JPY
Revenue IFRSPrior1InterimDuration_jpcrp040300-ssr_E36976-000DiagnosticsAndLifeSciencesReportableSegmentMember62561000000JPY
Revenue IFRSPrior1InterimDuration_ReportableSegmentsMember172305000000JPY
Revenue IFRSPrior1InterimDuration_ReconcilingItemsMember1557000000JPY
Revenue IFRSPrior1InterimDuration173863000000JPY
Operating profit loss IFRSPrior1InterimDuration_jpcrp040300-ssr_E36976-000DiabetesManagementReportableSegmentMember6361000000JPY
Operating profit loss IFRSPrior1InterimDuration_jpcrp040300-ssr_E36976-000HealthcareSolutionsReportableSegmentMember3635000000JPY
Operating profit loss IFRSPrior1InterimDuration_jpcrp040300-ssr_E36976-000DiagnosticsAndLifeSciencesReportableSegmentMember3494000000JPY
Operating profit loss IFRSPrior1InterimDuration_ReportableSegmentsMember13491000000JPY
Operating profit loss IFRSPrior1InterimDuration_ReconcilingItemsMember-4278000000JPY
Operating profit loss IFRSPrior1InterimDuration9212000000JPY
Finance income IFRSPrior1InterimDuration1414000000JPY
Finance costs IFRSPrior1InterimDuration3215000000JPY
Profit loss before tax IFRSPrior1InterimDuration7411000000JPY
Depreciation and amortization operating expenses IFRSPrior1InterimDuration_jpcrp040300-ssr_E36976-000DiabetesManagementReportableSegmentMember3323000000JPY
Depreciation and amortization operating expenses IFRSPrior1InterimDuration_jpcrp040300-ssr_E36976-000HealthcareSolutionsReportableSegmentMember4984000000JPY
Depreciation and amortization operating expenses IFRSPrior1InterimDuration_jpcrp040300-ssr_E36976-000DiagnosticsAndLifeSciencesReportableSegmentMember5661000000JPY
Depreciation and amortization operating expenses IFRSPrior1InterimDuration_ReportableSegmentsMember13970000000JPY
Depreciation and amortization operating expenses IFRSPrior1InterimDuration_ReconcilingItemsMember340000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2025-03-31pass rounding
balance sheet identityconsolidated 2025-09-30pass rounding
dei present pass
period resolution pass
statement vs summary · net income attributable to parentconsolidated 2024-04-01/2024-09-30pass
statement vs summary · net income attributable to parentconsolidated 2025-04-01/2025-09-30pass
statement vs summary · operating cash flowconsolidated 2024-04-01/2024-09-30pass
statement vs summary · operating cash flowconsolidated 2025-04-01/2025-09-30pass
statement vs summary · revenueconsolidated 2024-04-01/2024-09-30pass
statement vs summary · revenueconsolidated 2025-04-01/2025-09-30pass
statement vs summary · total assetsconsolidated 2025-03-31pass
statement vs summary · total assetsconsolidated 2025-09-30pass